PF-06939999, a Potent and Selective PRMT5 Inhibitor, in Patients with Advanced or Metastatic Solid Tumors: A Phase 1 Dose Escalation Study.
JOURNAL OF CLINICAL ONCOLOGY(2021)
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
JOURNAL OF CLINICAL ONCOLOGY(2021)